Consolidated Statements of Earnings - USD ($) shares in Thousands, $ in Millions		3 Months Ended		9 Months Ended
		Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Revenues:
Net earned premiums, principally supplemental health insurance	[1]	$ 3,372	$ 3,328	$ 10,223	$ 10,109
Net investment income		1,067	1,006	3,103	3,100
Net investment gains (losses)		275	(1,408)	(1,109)	239
Other income (loss)		26	23	81	76
Total revenues		4,740	2,949	12,298	13,524
Benefits and expenses:
Benefits and claims, excluding reserve remeasurement		2,016	2,003	6,049	6,042
Reserve remeasurement (gains) losses		(580)	(408)	(658)	(515)
Total benefits and claims, net		1,436	1,595	5,391	5,527
Acquisition and operating expenses:
Amortization of deferred policy acquisition costs		218	214	655	638
Insurance commissions		254	251	745	751
Insurance and other expenses		781	747	2,387	2,179
Interest expense		57	50	159	147
Total acquisition and operating expenses		1,310	1,262	3,946	3,715
Total benefits and expenses		2,746	2,857	9,337	9,242
Earnings before income taxes		1,994	92	2,961	4,282
Income taxes		355	185	694	741
Net earnings		$ 1,639	$ (93)	$ 2,267	$ 3,541
Net earnings per share:
Basic (in dollars per share)		$ 3.09	$ (0.17)	$ 4.22	$ 6.26
Diluted (in dollars per share)		$ 3.08	$ (0.17)	$ 4.21	$ 6.23
Weighted-average outstanding common shares used in computing earnings per share (In thousands):
Basic (in shares)		530,050	557,899	537,095	565,757
Diluted (in shares)		532,015	560,414	539,052	568,216
Cash dividends per share		$ 0.58	$ 0.50	$ 1.74	$ 1.50

[1] Includes a gain (loss) of $(55) and $(75) for the three-month periods and $(55) and $(80) for the nine-month periods ended September 30, 2025 and 2024, respectively, related to remeasurement of the deferred profit liability for limited-payment contracts.